TCT 2018 | LRP: Infrared Technology for the Detection of Vulnerable Patients and Plaques

Despite optimal medical treatment and modification of risk factors, patients may spend long periods without symptoms and then experience acute coronary syndrome without any prior indication that may allow us to predict the time of occurrence.

TCT 2018 | LRP: tecnología infrarroja para detectar pacientes y placas vulnerablesThis is why the possibility of detecting patients with vulnerable plaques and who are at higher risk is very important.

 

Near-infrared spectroscopy (NIRS) is available with a dual catheter for intravascular ultrasound (IVUS).

 

This study included 1563 patients with suspected coronary disease. NIRS-IVUS imaging was performed in two or more arteries, and patient- and artery-level analyses were carried out.

 

As regards the patient-level analysis, the risk of experiencing an event within 24 months for each 100-unit increase in maxLCBI4mm (lipid load index by NIRS) was 18%. The risk was 12.6% higher with maxLCBI4mm ≥400, compared with 6.3% for patients with maxLCBI4mm <400.

 

NIRS seems to be far from clinical practice, but it may help with the detection of non-culprit plaque or in patients who are at high risk of developing it in the future.

 

Original title: LRP (LIPID RICH PLAQUE STUDY) Assessment of Coronary Near-Infrared Spectroscopy Imaging to Detect Vulnerable Plaques and Vulnerable Patients.

Presenter: Ron Waksman.

 

LIPID-RICH-PLAQUE-STUDY-presentación


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...